Skip to main content
SpringerLink
Log in

Biologisch zielgerichtete medikamentöse Therapie

  • Chapter
Praxis der Viszeralchirurgie Onkologische Chirurgie

  • 4343 Accesses

Zusammenfassung

Neben den klassischen Zytostatika haben sich sog. biologisch zielgerichtete Wirkstoffe in der Systemtherapie viszeraler Tumorerkrankungen etabliert. Entsprechend des typischen Entwicklungszyklus pharmazeutischer Produkte ist deren Wirksamkeit bislang vor allem für die Therapie fortgeschrittener Tumorstadien belegt. Der Stellenwert biologisch zielgerichteter Therapien in der adjuvanten Indikation ist noch ganz überwiegend in klinischer Überprüfung.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 269.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Abbrederis K, Kremer M, Schuhmacher C (2008) Bevacizuman (Avastin) bedingte ischämische Anastomosenperforation 10 Monate postoperativ: Ein Fallbericht. Chirurg 79: 354–355

    Article  Google Scholar 

  • Amado RG, Wolf M, Peeters M, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626–1634

    Article  CAS  PubMed  Google Scholar 

  • Bach F, Uddin FJ, Burke D (2007) Angiopoietins in malignancy. Eur J Surg Oncol 33: 7–15

    CAS  PubMed  Google Scholar 

  • Baselga J, Tripathy D, Mendelsohn J, et al. (1996) Phase II study of weekly intravenous recombinant humanized antip185 monoclonal antibody in patients with HER-2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737–744

    CAS  PubMed  Google Scholar 

  • Beekman KW, Colevas AD, Cooney K, et al. (2006) Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer 4: 299–302

    Article  CAS  PubMed  Google Scholar 

  • Blazer DG, Kishi Y, Maru DM, et al. (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26: 5344–5351

    Article  PubMed  Google Scholar 

  • Bokemeyer C, Bondarenko I, Makhson A, et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the firstline treatment of metastatic colorectal cancer. J Clin Oncol 27: 663–667

    Article  CAS  PubMed  Google Scholar 

  • Bonner JA, Harari PM, Giralt J et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567–578

    Article  CAS  PubMed  Google Scholar 

  • Brooks PC, Clark RAF, Cheresh DA (1994) Requirement of vascular integrin avb3 for angiogenesis. Science 2674: 569–571

    Article  Google Scholar 

  • Bunn PA, Thatcher N (2008) Conclusion. The Oncologist 13(suppl 1): 37–46

    Article  PubMed  Google Scholar 

  • Cannistra SA, Matulonis U, Penson R, et al. (2006) Bevacizumab in patients with platinum-resistant ovarian cancer. J Clin Oncol 24(suppl 18): 5006 (abstr)

    Google Scholar 

  • Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Eng J Med 358: 1160–1174

    Article  CAS  Google Scholar 

  • Cunningham D, Humblet Y, Siena S, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345

    Article  CAS  PubMed  Google Scholar 

  • Demetri GD, van Oosterom AT, Garrett CR, et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329–1338

    Article  CAS  PubMed  Google Scholar 

  • Di Nicolantio F, Martini M, Molinari F, et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705–5712

    Article  Google Scholar 

  • Duda DG (2006) Antiangiogenesis and drug delivery to tumors: bench to bedside and back. Cancer Research 66: 3967–3970

    Article  CAS  PubMed  Google Scholar 

  • Ellis LM, Curley SA, Grothey A (2005) Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 23: 4853–4854

    Article  CAS  PubMed  Google Scholar 

  • Escudier B, Eisen T, Stadler WM, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–134

    Article  CAS  PubMed  Google Scholar 

  • Escudier B, et al. (2007) Sunitinib in advanced renal cell carcinoma. Lancet 370: 2103–2111

    Article  PubMed  Google Scholar 

  • Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391–399

    Article  CAS  PubMed  Google Scholar 

  • Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186

    CAS  PubMed  Google Scholar 

  • Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4–6

    Article  CAS  PubMed  Google Scholar 

  • Geyer CE, Forster J, Lindquist D, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733–2743

    Article  CAS  PubMed  Google Scholar 

  • Giantonio BJ, Catalano PJ, Meropol NJ, et al. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544

    Article  CAS  PubMed  Google Scholar 

  • Gordon MS, Margolin K, Talpaz M, et al. (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843–849

    CAS  PubMed  Google Scholar 

  • Graff JR, McNulty AM, Hanna KR, et al. (2005) The protein kinase CB-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT Pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65: 7462–7469

    Article  CAS  PubMed  Google Scholar 

  • Han SW, Kim TY, Hwang PG et al. (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in nonsmall-cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493–2501

    Article  CAS  PubMed  Google Scholar 

  • Heger U, Weitz J, Lordick F (2008) Indications for pre-and postoperative treatment with imatinib for GIST. Chirurg 79: 630–637

    Article  CAS  PubMed  Google Scholar 

  • Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011–1027

    Article  CAS  PubMed  Google Scholar 

  • Howdieshell TR, Callaway D, Webb WL, et al. (2001) Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res 96: 173–180

    Article  CAS  PubMed  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2341

    Article  CAS  PubMed  Google Scholar 

  • Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58–62

    Article  CAS  PubMed  Google Scholar 

  • Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040–2048

    Article  CAS  PubMed  Google Scholar 

  • Kang SP, Saif MW (2007) Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer identification, prevention, and management. J Support Onco1 5: 451–457

    CAS  Google Scholar 

  • Kang X, Patel D, Ng S, et al. (2007) High affinity Fc receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab. J Clin Oncol 25:Suppl: 128s (abstract)

    Google Scholar 

  • Karapetis CS, Khambata-Ford S, Jonker DJ, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757–1765

    Article  CAS  PubMed  Google Scholar 

  • Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews Cancer 6: 803–812

    Article  CAS  PubMed  Google Scholar 

  • Lièvre A, Bachet JB, Boige V, et al. (2008) KRAS Mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374–379

    Article  PubMed  Google Scholar 

  • Linardou H, Dahabre I, Kanaloupiti D, et al. (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and metaanalysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9: 962–972

    Article  CAS  PubMed  Google Scholar 

  • Llovet JM, Ricci S, Mazzaferro V, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378–390

    Article  CAS  PubMed  Google Scholar 

  • Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M (2006) Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. In J Radiat Oncol Biol Phys 64: 1295–1297

    Article  CAS  Google Scholar 

  • Lordick F, Leon-Chong J, Kang Y, et al. (2007) Her2 status of advanced gastric cancer is similar in Europe and Asia. Ann Oncol 18(suppl 7): abstr. 253

    Google Scholar 

  • Lordick F, Siewert JR (2008) Bevacizumab (Avastin®) related surgical complications. Chirurg 79: 356–360

    Article  CAS  PubMed  Google Scholar 

  • Maitra A, Hruban RH (2008) Pancreatic cancer. Annu Rev Pathol Mech Dis 3: 157–188

    Article  CAS  Google Scholar 

  • Makinde T, Agrawal DK (2008) Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease. J Cell Mol Med 12: 810–828

    Article  CAS  PubMed  Google Scholar 

  • Manegold C, Lurje G, Pohl A, et al. Can we predict the response to epidermal growth factor receptor targeted therapy? Target Oncol 3: 87–99

    Google Scholar 

  • Miller KD, Wang M, Gralow J et al. (2005) A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 94: S279

    Article  Google Scholar 

  • Moore MJ, Goldstein D, Hamm J, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960–1966

    Article  CAS  PubMed  Google Scholar 

  • Moroni M, Sartore-Bianchi A, Veronese S, Siena S (2008) EGFR FISH in colorectal cancer: what is the current reality? Lancet Oncol 9: 402–403

    Article  PubMed  Google Scholar 

  • Motzer RJ, Hutson TE, Tomczak P, et al. (2007) Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356:115–124

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Michaelson MD, Redman BG, et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16–24

    Article  CAS  PubMed  Google Scholar 

  • Oliner J, Min H, Yu D, et al. (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 5: 507–516

    Article  Google Scholar 

  • Pérez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-smallcell lung cancer. J Clin Oncol 22: 3238–3247

    Google Scholar 

  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer. N Engl J Med 353: 1659–1672

    Article  CAS  PubMed  Google Scholar 

  • Riely GJ, Pao W, Pham D et al.(2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: 839–844

    Article  CAS  PubMed  Google Scholar 

  • Roman CD, Choy H, Nanney L, et al. (2002) Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 105: 43–50

    Article  CAS  PubMed  Google Scholar 

  • Romond EH, Perez EA, Bryant J, et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. N Engl J Med 353: 1673–1684

    Article  CAS  PubMed  Google Scholar 

  • Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232

    Article  CAS  PubMed  Google Scholar 

  • Sandler A, Gray R, Perry MC et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542–2550

    Article  CAS  PubMed  Google Scholar 

  • Scappaticci FA, Fehrenbacher L, Cartwright T, et al. (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91: 173–179

    Article  CAS  PubMed  Google Scholar 

  • Shepherd FA, Rodrigues Pereira J, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

    Article  CAS  PubMed  Google Scholar 

  • Slamon DJ, Leyland-Jones B, Shak S, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med 344: 783–792

    Article  CAS  PubMed  Google Scholar 

  • Sleijfer S, Wiemer E, Verweij J (2008) Drug Insight: gastrointestinal stromal tumors (GIST) — the solid tumor model for cancer-specific treatment. Nature Clinical Practice Oncology 5: 102–111

    Article  CAS  PubMed  Google Scholar 

  • Sugrue M, Kozloff M, Hainsworth J, et al. (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol 24(suppl 18): 3535 (abstr)

    Google Scholar 

  • Teicher BA (2006) Protein kinase C as a therapeutic target. Clin Cance Res 12: 5336–5345

    Article  CAS  Google Scholar 

  • Van Cutsem E, Kang YK, Chung HC, et al. (2009) Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol (18S): abstract LBA4509

    Google Scholar 

  • Van Cutsem E, Köhne CH, Hitre E, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408–1417

    Article  PubMed  Google Scholar 

  • Van Cutsem E, Peeters M, Siena S, et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658–1664

    Article  PubMed  Google Scholar 

  • Vermorken JB, Mesia R, Rivera F, et al. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116–1127

    Article  CAS  PubMed  Google Scholar 

  • Yang XD (2001) Development of ABX-EGFR, a fully human anti EGFR monoclonal antibody for cancer therapy. Crit Rev Hematol Oncol 38: 17–23

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik III, Hämatologie und Onkologie Klinikum Braunschweig, Celler Straße 38, 38114, Braunschweig

    Prof. Dr. med. F. Lordick

Authors
  1. Prof. Dr. med. F. Lordick
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinikum Heidelberg, Im Neuenheimer Feld 672, 69120, Heidelberg

    J. R. Siewert (Leitender Ärztlicher Direktor und Vorstandsvorsitzender) (Leitender Ärztlicher Direktor und Vorstandsvorsitzender)

  2. Zentrum für Operative Medizin I, Klinikum der Philipps-Universität, Baldinger Straße, 35043, Marburg

    Matthias Rothmund

  3. Universitätsklinik und Poliklinik, Medizinische Fakultät der RWTH, Pauwelsstraße 30, 52057, Aachen

    Volker Schumpelick

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lordick, F. (2010). Biologisch zielgerichtete medikamentöse Therapie. In: Siewert, J.R., Rothmund, M., Schumpelick, V. (eds) Praxis der Viszeralchirurgie Onkologische Chirurgie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-03808-2_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-03808-2_24

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-03807-5

  • Online ISBN: 978-3-642-03808-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation